Abstract
HMG-CoA reductase inhibitors (‘statins’) represent the most effective and widely prescribed drugs currently available for the reduction of low-density lipoprotein cholesterol, a critical therapeutic target for primary and secondary prevention of cardiovascular atherosclerotic disease. In the face of the established lipid lowering and the emerging pleiotropic properties of statins, the patient population suitable for long-term statin treatment is expected to further expand. An overall positive safety and tolerability profile of statins has been established, although adverse events have been reported. Skeletal muscle-related events are the most common adverse events of statin treatment. Statin-induced myopathy can (rarely) manifest with severe and potentially fatal cases of rhabdomyolysis, thus rendering the identification of the underlying predisposing factors critical.
The purpose of this review is to summarize the factors that increase the risk of statin-related myopathy. Data from published clinical trials, meta-analyses, postmarketing studies, spontaneous report systems and case reports for rare effects were reviewed. Briefly, the epidemiology, clinical spectrum and molecular mechanisms of statin-associated myopathy are discussed. We further analyse in detail the risk factors that precipitate or increase the likelihood of statin-related myopathy. Individual demographic features, genetic factors and co-morbidities that may account for the significant inter-individual variability in the myopathic risk are presented. Physicochemical properties of statins have been implicated in the differential risk of currently marketed statins. Pharmacokinetic interactions with concomitant medications that interfere with statin metabolism and alter their systemic bioavailability are reviewed. Of particular clinical interest in cases of resistant dyslipidaemia is the interaction of statins with other classes of lipid-lowering agents; current data on the relative safety of available combinations are summarized. Finally, we provide an update of current guidelines for the prevention and management of statin myopathy.
The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins.
Similar content being viewed by others
References
Chatzizisis YS, Jonas M, Beigel R, et al. Attenuation of inflammation and expansive remodeling by valsartan alone or in combination with simvastatin in high-risk coronary atherosclerotic plaques. Atherosclerosis 2009; 203: 387–94
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292(5519): 1160–4
Grundy SM, Cleeman JI, Merz CN, et al., for the Coordinating Committee of the National Cholesterol Education Program and Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–39
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504
Schwarz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACLE study: a randomized controlled trial. JAMA 2001; 285: 1711–8
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7–22
Shepherd J, Blauw GJ, Murphy MB, et al., PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623–30
Sever PS, Dahlof B, Poulter NR, et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58
Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25(9): 649–63
Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol 2002; 13(6): 637–44
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al., and Writing Committee Members. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024–8
Bays H. Statin safety: an overview and assessment of the data: 2005. Am J Cardiol 2006; 97 Suppl. 8A: 6–26C
Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–90
Pedersen TR, Faergeman O, Kastelein JP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45
Law M, Rudnicka AR. Statin safety: evidence from the published literature. Am J Cardiol 2006; 97 Suppl. 8A: 52–60C
Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the Adverse Event Reporting System (AERS). Am J Cardiol 2006; 97 Suppl. 8A: 32–43C
Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–207
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59
Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97 Suppl.: 69–76C
US Food and Drug Administration. Office of Drug Safety annual report 2001 [online]. Available from URL: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm169925.htm. [Accessed 2009 Aug 5]
Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346(7): 539–40
Kashani A, Phillips CO, Foody JA, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788–97
Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–14
Silva MA, Swanson AC, Gandhi PG, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26–33
Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008; 102(12): 1654–62
Vaklavas C, Chatzizisis YS, Ziakas A, et al. Molecular basis of statin-associated myopathy. Atherosclerosis 2009 Jan; 202(1): 18–28
Morita I, Sato I, Ma L, et al. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium 1997; 5(2): 107–13
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49: 2231–7
Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57: 62–6
Chatzizisis YS, Vaklavas C, Giannoglou GD. Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy [letter]? Am J Cardiol 2008 Apr 1; 101(7): 1071
Sakamoto K, Mikami H, Kimura J. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. Br J Pharmacol 2008; 154: 1482–90
Dorajoo R, Pereira BP, Yu Z, et al. Role of multi-drug resistance-associated protein-1 transporter in statin induced myopathy. Life Sci 2008; 82: 823–30
Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19(1): 26–37
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71–105
Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109 Suppl. III: III50–7
Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53(2): 299–336
White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963–70
Schech S, Graham D, Staffa J, et al. Risk factors for statinassociated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007; 16(3): 352–8
Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78(4): 330–41
Tan C-E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 1182–6
Matsuzawa Y, Kita T, Mabuchi H, et al., for the J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51 321 Japanese hypercholesterolemic patients: implication of the J-LIT study, a large scale nationwide cohort study. Circ J 2003; 67: 287–94
Morales D, Chung N, Zhu J-R, et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr Med Res Opin 2004; 20: 1235–43
Tan CE, Loh LM, Tai ES. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med J 2003; 44: 635–8
Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083–105
Wang A, Yu BN, Luo CH, et al. Ile 118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005; 60: 843–8
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99(3): 410–4
Food and Drug Administration Center for Drug Evaluation and Research. FDA Public Health Advisory on Crestor (rosuvastatin) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051756.htm [Accessed 2009 Aug 1]
Saito M, Hirata-Koizumi M, Urano T, et al. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 2005; 30: 21–37
Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004; 4: 247–55
Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546–51
Morimoto K, Ueda S, Seki N, et al. OATPC(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients. Clin Pharmacol Ther 2005; 77: P21
Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6: 7
The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359(8): 789–99
Leung NM, Ooi TC, McQueen MJ. Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders. Arch Intern Med 2000; 132: 418–9
Franc S, Bruckert E, Giral P, et al. Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents. Presse Med 1997; 26: 1855–8
Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve 2008; 38: 1101–7
Vladutiu R, Isackson P, Peltier W, et al. Genetic risk factors and metabolic abnormalities associated with lipid lowering therapies. Muscle Nerve 2006; 34(2): 153–62
Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260–9
Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32 225 diabetic and nondiabetic patients. Clin Ther 2007; 29(8): 1761–70
Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med 2007; 18: 90–100
Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin induced myopathy. Can Fam Physician 2007; 53(3): 428–31
Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286
Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49: 1753–62
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289(13): 1681–90
Ronaldson KJ, O’Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 2006; 29(11): 1061–7
Wong WM, Wai-Hung Shek T, Chan KH. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy. Gastroenterol Hepatol 2004; 19(8): 952–3
Finsterer J, Zuntner G. Rhabdomyolysis from simvastatin triggered by infection and muscle exertion. South Med J 2005; 98(8): 827–9
Betrosian A, Thireos E, Kofinas G, et al. Bacterial sepsis-induced rhabdomyolysis. Intensive Care Med 1999; 25: 469–74
Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997; 46: 1206–10
Wilhelmi M, Winterhalter M, Fisher S, et al. Massive postoperative rhabdomyolysis following combined CABG/ abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 2002; 16(5): 471–5
East C, Alivizatos PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318(1): 47–8
Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95(5): 658–60
Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400–9
Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160mg/day. Am J Cardiol 1997; 257(79): 38–42
Rosenson RS, Bays HE. Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160mg per day. Am J Cardiol 2003; 91: 878–81
Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163–74
Ziegler K, Stunkel W. Tissue-selective action of pravastatin due to hepatocellular uptake via sodium-independent bile acid transporter. Biochem Biophys Acta 1992; 1139: 203–9
Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97 Suppl.: 27–31C
Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664–5
Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–4
Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–82
Lee AJ, Maddix DS. Rhabdomyolysis secondary to drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26–31
Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267–74
Lewin JJ, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36: 1546–8
Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20: 1066–71
Lenhard JM, Croom DK, Weiel JE, et al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 2625–9
Chuk SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002; 1(1): 5–11
Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006; 12(36): 4771–83
Pichard L, Domergue J, Fourtanier G, et al. Metabolism of the new immumosuppresor cyclosporin G by human liver cytochrome P450. Biochem Pharmacol 1996; 51(5): 591–8
Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318: 46–7
Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Therapeut 2002; 40: 439–50
Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413–28
Moguorosi A, Bradley B, Showealter A, et al. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599–602
Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225–9
Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Phermacother 2001; 35: 908–17
Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999; 138: 151–5
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005; 95: 120–2
Franssen R, Vergeer M, Stroes ES, et al. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009 Feb; 11(2): 89–94
Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–90
Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505–12
Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfi brozil and statins. J Pharmacol Exp Ther 2002; 301: 1042–51
Schoonjans K, Steals B, Auwerx J. Role of peroxisome proliferator activated receptor in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907–25
Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538–44
Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109: 597–8
Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008; 101 Suppl.: 3–8B
Fux R, Morike K, Gundel UF, et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004; 140: 671–2
Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006; 22(2): 141–4
Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe addon to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005 May; 80(5): 587–95
Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006 Jan 15; 97(2): 223–8
Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008 Dec 1; 102(11): 1489–94
Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495–501
Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99 Suppl.: 3–18C
Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76 Suppl.: 80–3A
McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97 Suppl.: 89–94C
Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008; 19(8): 568–74
Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008; 101: 490–6
Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 2006; 28: 933–42
Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002; 144: 674–7
Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol 2005; 8: 197–9
Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101(4): 483–5
Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42: 341–6
Backes JM, Moriarty PM, Ruisinger JF, et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007; 100: 554–5
Mackie BD, Satija S, Nell C, et al. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy [letter]. Am J Cardiol 2007; 99: 291
Gadarla M, Kearns A, Thompson PD. Efficacy of rosuvastatin (5mg and 10mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008; 10(12): 1747–8
Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183–92
Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007; 13: 11–6
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest to declare. Y.S. Chatzizisis and K.C. Koskinas contributed equally to this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chatzizisis, Y.S., Koskinas, K.C., Misirli, G. et al. Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug-Safety 33, 171–187 (2010). https://doi.org/10.2165/11319380-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11319380-000000000-00000